Valuation dashboard for Pasithea Therapeutics Corp. (KTTA) with P/E N/A, P/B 0.07, EV/EBITDA 1958.83 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $0.49, KTTA has negative trailing earnings (P/E not meaningful) and an ROE of -49.49%. Market capitalisation stands at $16M.
Balance sheet quality for KTTA: current ratio of 11.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.07 |
| EV / EBITDA | 1958.83 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $7.85 |
| vs Current Price | +1501.0% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| KTTA | Pasithea Therapeutics Corp. | $16M | 0.07 | -49.5% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $0.49 |
| Market Cap | $16M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -49.49% |
| Return on Invested Capital | -48.04% |
| Return on Assets | -41.18% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AIM · CYCN · IBO · KALA · NBY · PLRZ · QNRX
Explore sector: Healthcare · Biotechnology
More sections of KTTA: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks